Par Pharmaceutical completes acquisition of Anchen
Purchase brings five commercialised products and 27 ANDAs on file with the US FDA
US-based speciality pharmaceutical company Par Pharmaceutical Companies has completed its US$410m acquisition of Anchen Pharmaceuticals, a privately held speciality pharmaceutical company focused on developing and commercialising extended release and niche generic products.
Headquartered in Irvine, California, Anchen is a profitable, fully integrated pharmaceutical com-pany with five commercialised products, 27 AN-DAs on file with the US FDA, five of which are believed to be first-to-file, and approximately 26 additional products in development.
Anchen has approximately 200 employees and more than 72,000ft2 of expandable manufacturing and warehouse facilities with state-of-the-art equipment.
Through its wholly owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, Par Pharmaceutical Companies develops, manufactures and markets higher-barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals.
